Amcinonide
Amcinonide: 3 brands, 5 generics; first approved Jun 13, 1988; generic available.
Generic available: 5 ANDA applications approved.
Brand (NDA) products
- CYCLOCORTRLDASTELLASNDA 0197291988
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1% LOTION TOPICAL Discontinued — - CYCLOCORTRLDASTELLASNDA 018116—2 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.025% CREAM TOPICAL Discontinued — 0.1% CREAM TOPICAL Discontinued — - CYCLOCORTRLDASTELLASNDA 018498—
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1% OINTMENT TOPICAL Discontinued —
Generic (ANDA) products (5)
- AMCINONIDEGENUS LIFESCIENCESANDA 0760652003
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1% CREAM TOPICAL Discontinued — - AMCINONIDETARO PHARM INDSANDA 0763672003
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1% OINTMENT TOPICAL Discontinued — - AMCINONIDERSGENUSANDA 0760962002
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1% OINTMENT TOPICAL Rx — - AMCINONIDERSSOLUBIOMIXANDA 0763292002
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1% LOTION TOPICAL Rx — - AMCINONIDERSTARO PHARM INDSANDA 0762292002
Approved strengths under this FDA application. Strength Dosage form Route Status TE 0.1% CREAM TOPICAL Rx —
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
Approvals span 1988–2003 across 8 FDA applications.
Amcinonide: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Go beyond the database.
Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.